Big pharma will feel the heat over the next 6 years as small and mid-size developers eat away at their market share and profit margins. But as far as in-house orphan drug units go, GSK has bucked the trend and rocketed up the ranking, along with the likes of Pharmacyclics who shoot up an impressive 65 places from 2013.
